MARA Holdings
MARA
Coinbase
COIN
Meta Platforms
META
Vale SA
VALE
Alphabet-C
GOOG
US Stock MarketDetailed Quotes
TELO Telomir Pharmaceuticals
- 4.862
- +0.112+2.35%
Trading Jan 24 13:36 ET
143.95MMarket Cap-6.27P/E (TTM)
4.920High4.670Low31.08KVolume4.850Open4.750Pre Close149.08KTurnover0.18%Turnover RatioLossP/E (Static)29.61MShares20.72052wk High324.11P/B84.91MFloat Cap3.11052wk Low--Dividend TTM17.46MShs Float20.720Historical High--Div YieldTTM5.26%Amplitude3.110Historical Low4.796Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Telomir Pharmaceuticals Stock Forum
From an investment perspective, these preclinical results substantially enhance TELO's value proposition. With a market cap of just $135M, the company appears undervalued given the broad therapeutic potential of Telomir-1. The addressable market spans rare diseases like progeria (~400 patients globally) to massive markets like Type 2 diabetes, creating a compelling risk-reward profile.
The metal ion regulation mechanism is particularly...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release
7. Remember, some stocks may get pumped WITHOUT any catalyst
8. NEVER be a blind follower.
LASTLY, If y...
From an investment perspective, these preclinical results substantially enhance TELO's value proposition. With a market cap of just $135M, the company appears undervalued given the broad therapeutic potential of Telomir-1. The addressable market spans rare diseases like progeria (~400 patients globally) to massive markets like Type 2 diabetes, creating a compelling risk-reward profile.
The metal ion regulation mechanism is particular...
The preclinical study results for Telomir-1 represent a significant scientific breakthrough in addressing accelerated aging conditions. The restoration of lifespan in wrn-1-mutated C. elegans to normal levels demonstrates robust proof-of-concept for Telomir-1's mechanism of action. The normalization of physiological parameters like movement velocity provides tangible evidence of improved healthspan, not just lifespan.
The comp...
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
Tuesday, 7th January at 8:00 am
MIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ("Telomir"), an emerging leader in age-reversal science focused on treating the root causes of diseases rather than just their symptoms, announced today potentially grou...
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
Monday, 23rd December at 7:30 am
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), or the "Company", an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is a promising development as the company explores Telomir-1 for the...
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
Thursday, 12th December at 8:30 am
Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential.
MIAMI, FL / ACCESSWIRE / December 12, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ("Telomir" or the "Company"...
NFA = not financial advice
RTH = regular trading hours
AH = after hours
LTB = left to borrow
CTB = cost to borrow
*I removed $AmpliTech Group (AMPG.US)$ because it just announced direct offering of $2M valued $1.6/shares. Now there are offerings where market defies it and continues to rally. We shall see tomorrow
$Nuburu (BURU.US)$ PR AH 12/11: Resolved compliance issue. Up AH. Low float. CTB...
The transaction did not involve the issuance of any warrants. This transaction follows a $5 million non-dilutive line of credit extende...
No comment yet